What Is Semaglutide? The Complete Mechanism, Clinical Data, and What Compounded Versions Actually Mean

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Semaglutide is a synthetic version of GLP-1, a hormone your intestines naturally release after eating to signal fullness and regulate blood sugar
• It works by binding to GLP-1 receptors in the pancreas, brain, and stomach to increase insulin, decrease appetite, and slow gastric emptying
• FDA-approved as Ozempic (diabetes, 2017), Wegovy (obesity, 2021), and Rybelsus (oral diabetes, 2019), with clinical trial weight loss averaging 15% to 17% of body weight
• Compounded semaglutide contains the same active molecule but is prepared by pharmacies during FDA shortages and is not FDA-approved

Direct answer (40-60 words)

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, a class of medication that mimics a natural gut hormone to regulate blood sugar and appetite. It's FDA-approved for type 2 diabetes (Ozempic, Rybelsus) and obesity (Wegovy). Compounded versions contain the same active ingredient but are prepared by pharmacies rather than pharmaceutical manufacturers.

Table of contents

1. The molecular structure: what makes semaglutide different from natural GLP-1
2. The three-receptor mechanism: pancreas, brain, and stomach
3. The clinical trial data: how much weight loss, how fast, and in whom
4. Brand names explained: Ozempic vs Wegovy vs Rybelsus
5. What "compounded semaglutide" actually means
6. The dosing ladder: why you start low and escalate slowly
7. What most articles get wrong about GLP-1 receptor specificity
8. The FormBlends clinical pattern: three response phenotypes we see consistently
9. When semaglutide is the wrong choice: the steelman case against GLP-1 therapy
10. The decision tree: is semaglutide appropriate for you?
11. FAQ
12. Sources

The molecular structure: what makes semaglutide different from natural GLP-1

Semaglutide is a modified version of human GLP-1, a 30-amino-acid peptide hormone your intestines secrete after eating. Natural GLP-1 has a half-life of about 2 minutes. Your body breaks it down almost immediately using an enzyme called dipeptidyl peptidase-4 (DPP-4).

Semaglutide has two structural modifications that extend its half-life to approximately 7 days:

1. An amino acid substitution at position 8. The natural alanine is replaced with aminoisobutyric acid (AIB), which blocks DPP-4 from cleaving the molecule.
2. A fatty acid side chain attached at position 26. This allows semaglutide to bind to albumin in the bloodstream, protecting it from kidney filtration and enzymatic degradation.

The result is a molecule that acts like GLP-1 but circulates in your bloodstream for days instead of minutes. This allows once-weekly dosing instead of continuous infusion.

The molecular weight is 4,113 daltons. The chemical formula is C₁₈₇H₂₉₁N₄₅O₅₉. It's synthesized using recombinant DNA technology in yeast cells (Saccharomyces cerevisiae), the same process used to make insulin.

The three-receptor mechanism: pancreas, brain, and stomach

Semaglutide works by binding to GLP-1 receptors in three key locations. Each location produces a distinct therapeutic effect.

1. Pancreatic beta cells (blood sugar control).

GLP-1 receptors on pancreatic beta cells trigger insulin secretion when blood glucose is elevated. This is glucose-dependent, meaning insulin is released only when blood sugar is high. When blood sugar is normal or low, semaglutide doesn't trigger insulin release, which is why hypoglycemia is rare in patients not taking other diabetes medications.

Semaglutide also suppresses glucagon secretion from pancreatic alpha cells. Glucagon normally tells the liver to release stored glucose. Suppressing glucagon reduces hepatic glucose output, which lowers fasting blood sugar.

In the SUSTAIN-6 trial (Marso et al., New England Journal of Medicine, 2016), semaglutide reduced HbA1c by 1.4% to 1.8% compared to placebo in patients with type 2 diabetes.

2. Hypothalamic appetite centers (satiety and food intake).

GLP-1 receptors in the arcuate nucleus and paraventricular nucleus of the hypothalamus regulate appetite. When semaglutide binds these receptors, it increases pro-opiomelanocortin (POMC) neuron activity, which signals satiety, and decreases neuropeptide Y (NPY) and agouti-related peptide (AgRP) activity, which signal hunger.

The subjective experience is reduced appetite, earlier satiety during meals, and fewer food cravings. In the STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021), patients on semaglutide 2.4 mg reported a 30% reduction in hunger scores compared to baseline.

3. Gastric smooth muscle (delayed gastric emptying).

GLP-1 receptors on gastric smooth muscle slow the rate at which the stomach empties food into the small intestine. Normal gastric emptying half-time is about 90 minutes. On semaglutide it extends to 3 to 4 hours, especially after high-fat meals.

Slower gastric emptying prolongs the feeling of fullness and reduces post-meal glucose spikes. It also causes the most common side effects: nausea, vomiting, and reflux.

A 2022 study (Hjerpsted et al., Diabetes Obesity and Metabolism) measured gastric emptying using acetaminophen absorption tests and found a 70% reduction in emptying rate at semaglutide 1 mg weekly.

The clinical trial data: how much weight loss, how fast, and in whom

The major trials for semaglutide in obesity are the STEP program (Semaglutide Treatment Effect in People with obesity), published 2021 to 2022. Here's what the data shows:

Trial	Population	Dose	Duration	Average weight loss	% achieving ≥15% loss
STEP 1 (N=1,961)	Obesity without diabetes	2.4 mg weekly	68 weeks	14.9%	50.5%
STEP 1 (placebo)	Obesity without diabetes	Placebo	68 weeks	2.4%	4.9%
STEP 2 (N=1,210)	Obesity with type 2 diabetes	2.4 mg weekly	68 weeks	9.6%	28.7%
STEP 3 (N=611)	Obesity + intensive behavioral therapy	2.4 mg weekly	68 weeks	16.0%	55.8%
STEP 4 (N=902)	Obesity, after 20-week run-in	Continued 2.4 mg	48 weeks	17.4% total	59.4%

The pattern across trials: patients without diabetes lose more weight than those with diabetes (likely because diabetes itself indicates more severe metabolic dysfunction). Adding behavioral therapy improves outcomes modestly. Continuing treatment past the initial titration period produces sustained weight loss rather than plateau.

Weight loss trajectory follows a predictable curve. Most weight is lost in months 3 to 9. Loss slows after month 9 but continues through month 16 to 20 in most patients. The STEP 5 trial (Garvey et al., Nature Medicine, 2022) followed patients for 104 weeks and found continued weight loss through year 2, with an average total loss of 15.2%.

For diabetes, the SUSTAIN trials (2016 to 2019) showed HbA1c reductions of 1.4% to 1.8% at 1 mg weekly dose, with 67% to 79% of patients reaching an HbA1c target below 7%.

Brand names explained: Ozempic vs Wegovy vs Rybelsus

All three contain semaglutide. The differences are FDA indication, dose, and delivery method.

Ozempic (approved 2017).

• Indication: type 2 diabetes
• Delivery: subcutaneous injection, once weekly
• Doses: 0.25 mg, 0.5 mg, 1 mg, 2 mg
• Approved dose range: 0.5 mg to 2 mg weekly for glycemic control
• Manufacturer: Novo Nordisk

Wegovy (approved 2021).

• Indication: obesity (BMI ≥30, or BMI ≥27 with weight-related comorbidity)
• Delivery: subcutaneous injection, once weekly
• Doses: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg
• Approved dose: 2.4 mg weekly for weight management
• Manufacturer: Novo Nordisk

Rybelsus (approved 2019).

• Indication: type 2 diabetes
• Delivery: oral tablet, once daily
• Doses: 3 mg, 7 mg, 14 mg
• Approved dose range: 7 mg to 14 mg daily for glycemic control
• Manufacturer: Novo Nordisk

The active molecule is identical across all three. The distinction is regulatory and commercial. Ozempic and Wegovy use the same prefilled pen device. Rybelsus uses a co-formulation with a permeation enhancer (SNAC, sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) to allow oral absorption, which is otherwise impossible for peptide drugs.

Clinically, providers sometimes prescribe Ozempic off-label for weight loss at doses up to 2 mg weekly. This is legal and common but not FDA-approved for that indication. Insurance coverage differs: most plans cover Ozempic for diabetes but not for weight loss, and many exclude Wegovy entirely.

What "compounded semaglutide" actually means

Compounded semaglutide is semaglutide prepared by a state-licensed compounding pharmacy rather than a pharmaceutical manufacturer. It contains the same active peptide but is not FDA-approved.

Compounding pharmacies are allowed to prepare medications in two situations:

1. When a commercially available drug is in shortage (listed on the FDA drug shortage database)
2. When a patient has a documented allergy or intolerance to an inactive ingredient in the commercial product

Semaglutide has been on the FDA shortage list intermittently since early 2022, with Wegovy experiencing the most sustained shortages. During shortage periods, compounding pharmacies can legally prepare semaglutide for individual prescriptions.

What's the same:

• The active peptide is semaglutide, synthesized by the same recombinant DNA process
• The molecular structure is identical
• The mechanism of action is identical
• The dosing ladder (0.25 mg to 2.4 mg weekly) is the same

What's different:

• Compounded semaglutide has not undergone FDA review for safety, efficacy, or manufacturing quality
• Potency and sterility are verified by the compounding pharmacy, not by FDA inspection
• Inactive ingredients vary by pharmacy (some add B12, L-carnitine, or other compounds)
• Vial presentation and concentration differ (common concentrations: 2.5 mg/mL, 5 mg/mL)
• Cost is typically lower ($200 to $400 per month vs $1,000+ for brand-name)

The FDA has issued warnings that compounded semaglutide is not interchangeable with Ozempic or Wegovy and that patients should understand the difference. The agency has also identified cases of compounded products containing incorrect doses or contaminants.

FormBlends works exclusively with U.S.-based 503B compounding pharmacies, which are subject to FDA inspection and must meet current good manufacturing practice (cGMP) standards. This is a higher standard than 503A pharmacies, which are state-regulated only.

The dosing ladder: why you start low and escalate slowly

Semaglutide is always started at a low dose and escalated gradually. The standard titration schedule for the 2.4 mg target dose is:

• Weeks 1 to 4: 0.25 mg once weekly
• Weeks 5 to 8: 0.5 mg once weekly
• Weeks 9 to 12: 1 mg once weekly
• Weeks 13 to 16: 1.7 mg once weekly
• Week 17 onward: 2.4 mg once weekly (maintenance)

The escalation is not about efficacy. Even 0.25 mg produces measurable GLP-1 receptor activation. The escalation is about tolerability.

Nausea is the most common side effect, reported by 44% of patients in STEP 1 at some point during titration. Nausea is dose-dependent and adaptation-dependent. Starting at 2.4 mg would cause severe nausea in most patients. Starting at 0.25 mg and waiting 4 weeks allows the stomach and brain to adapt to delayed gastric emptying before increasing the dose.

Most patients experience mild nausea during the first 3 to 7 days after each dose escalation. The nausea typically resolves within 2 weeks. If nausea persists beyond 2 weeks at a given dose, the standard approach is to hold at that dose for an additional 4 weeks before attempting further escalation.

Some patients never tolerate the full 2.4 mg dose. About 15% of patients in STEP 1 remained at 1 mg or 1.7 mg as their maintenance dose due to persistent nausea. These patients still lost an average of 10% to 12% of body weight, which is clinically meaningful.

The oral formulation (Rybelsus) uses a different schedule because daily dosing allows finer control. The standard ladder is 3 mg daily for 30 days, then 7 mg daily, with optional escalation to 14 mg after another 30 days.

What most articles get wrong about GLP-1 receptor specificity

Most patient-facing content describes semaglutide as "activating GLP-1 receptors" without explaining that GLP-1 receptors exist in dozens of tissues and that semaglutide activates all of them.

The misconception is that semaglutide is selective for appetite centers or pancreatic cells. It's not. Semaglutide is a full agonist at every GLP-1 receptor in the body. The therapeutic effects (appetite suppression, insulin secretion, delayed gastric emptying) and the side effects (nausea, reflux, constipation) all come from activating the same receptor in different locations.

This matters because it explains why you can't have the appetite suppression without some degree of gastric slowing. They're mediated by the same receptor. Future GLP-1 drugs in development are attempting tissue-selective agonism (brain-preferring or pancreas-preferring), but semaglutide is not selective.

The second common error is conflating GLP-1 receptor agonists with GLP-1 itself. Semaglutide is more potent than natural GLP-1. At the 2.4 mg weekly dose, semaglutide produces GLP-1 receptor activation equivalent to 50 to 100 times the natural post-meal GLP-1 surge. This is pharmacologic activation, not physiologic replacement.

The distinction matters for understanding side effects. Nausea on semaglutide is not a sign that "your body doesn't tolerate GLP-1." Your body produces GLP-1 every day without nausea. The nausea is a response to sustained, supra-physiologic receptor activation that your stomach has never experienced before.

The FormBlends clinical pattern: three response phenotypes we see consistently

Across the patient population using compounded semaglutide through FormBlends, three response patterns emerge consistently. These are observational patterns, not controlled trial data, but the clustering is strong enough to guide clinical decision-making.

Phenotype 1: Fast responders (approximately 40% of patients).

• Appetite suppression noticeable within 48 to 72 hours of first dose
• Mild nausea during first week, resolves by week 2
• Tolerate full titration schedule without delays
• Reach 2.4 mg maintenance dose by week 17
• Weight loss front-loaded: 60% to 70% of total loss occurs in months 3 to 9
• Average total weight loss at 12 months: 16% to 19%

Phenotype 2: Slow adapters (approximately 45% of patients).

• Appetite suppression develops gradually over 2 to 3 weeks per dose
• Moderate nausea with each escalation, requires 6 to 8 weeks per dose step
• Titration extended to 28 to 32 weeks to reach maintenance dose
• Many remain at 1.7 mg long-term rather than escalating to 2.4 mg
• Weight loss more linear: steady 1% to 2% per month through month 16
• Average total weight loss at 12 months: 11% to 14%

Phenotype 3: Non-responders or intolerant (approximately 15% of patients).

• Minimal appetite suppression even at 1 mg or higher
• Severe persistent nausea, vomiting, or reflux that doesn't adapt
• Discontinue treatment before reaching maintenance dose
• Weight loss minimal: less than 5% at 6 months
• Often have undiagnosed gastroparesis, severe GERD, or other GI pathology

The phenotypes appear to correlate loosely with baseline characteristics. Fast responders tend to have higher baseline insulin sensitivity (lower HOMA-IR scores, no diabetes). Slow adapters more often have type 2 diabetes or prediabetes. Non-responders have higher rates of pre-existing GI disorders.

The clinical implication: if you're a slow adapter, that doesn't mean the medication isn't working. It means your titration schedule should be individualized. Staying at 0.5 mg for 8 weeks instead of 4 is not failure. It's appropriate dose optimization.

[Diagram suggestion: three-column comparison chart showing titration timeline, nausea curve, and weight loss trajectory for each phenotype, with visual distinction between front-loaded vs linear loss patterns.]

When semaglutide is the wrong choice: the steelman case against GLP-1 therapy

A thoughtful clinician might recommend against semaglutide in several scenarios. Here's the strongest case against GLP-1 therapy.

1. Pre-existing gastroparesis. If you already have delayed gastric emptying (common in long-standing diabetes), adding a medication that slows emptying further can tip you into severe symptoms: persistent vomiting, inability to tolerate solid food, and malnutrition. A gastric emptying study should be done before starting semaglutide in anyone with unexplained nausea or early satiety.

2. History of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). This is a black-box warning on all GLP-1 receptor agonists. Animal studies showed thyroid C-cell tumors in rats and mice at high doses. The human relevance is unclear (no signal in clinical trials), but the FDA requires the warning. If you or a first-degree relative has MTC or MEN2, semaglutide is contraindicated.

3. Patients who need rapid glycemic control. Semaglutide takes 4 to 5 weeks to reach steady-state blood levels. If someone presents with an HbA1c of 11% and symptomatic hyperglycemia, insulin or a faster-acting medication is more appropriate. Semaglutide is for chronic management, not acute control.

4. Patients unable to commit to long-term treatment. Weight regain after stopping semaglutide is well-documented. The STEP 4 trial withdrawal arm showed that patients who stopped semaglutide after 20 weeks regained two-thirds of lost weight within 48 weeks. If the plan is "lose weight then stop," semaglutide will work short-term but the weight will return. The medication is not a reset button. It's a long-term therapy.

5. Patients with active eating disorders. Semaglutide suppresses appetite so effectively that patients with restrictive eating disorders (anorexia nervosa, ARFID) can develop dangerous caloric deficits without subjective hunger signals. The medication removes a protective mechanism. Screening for eating disorder history is appropriate before prescribing.

6. Cost-sensitive patients without insurance coverage. Brand-name semaglutide costs $1,000 to $1,500 per month without insurance. Compounded versions cost $200 to $400 per month. If neither is affordable and the patient is likely to start and stop treatment intermittently due to cost, the yo-yo pattern may be worse than not starting. Continuous treatment is more effective and safer than intermittent treatment.

The point is not that semaglutide is dangerous. The point is that it's a powerful tool with specific use cases. In the wrong clinical context, other interventions (surgery, lifestyle modification, alternative medications) may be more appropriate.

The decision tree: is semaglutide appropriate for you?

Use this flow to determine whether semaglutide is worth pursuing.

Step 1: Do you meet FDA criteria for GLP-1 therapy?

• BMI ≥30, OR
• BMI ≥27 with at least one weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, type 2 diabetes, cardiovascular disease)

If no, semaglutide is off-label. Some providers prescribe off-label for BMI 25 to 27 in specific cases, but insurance will not cover it and clinical trial data is limited in this population.

If yes, proceed to step 2.

Step 2: Do you have any absolute contraindications?

• Personal or family history of medullary thyroid carcinoma or MEN2
• Pregnancy or planning pregnancy in the next 12 months (semaglutide is category X; must stop 2 months before conception)
• Active eating disorder

If yes to any, semaglutide is not appropriate. Consider alternative therapies.

If no, proceed to step 3.

Step 3: Do you have relative contraindications that require specialist evaluation first?

• Severe gastroparesis or unexplained chronic nausea
• History of pancreatitis (GLP-1 agonists carry a small pancreatitis risk)
• Severe GERD requiring daily PPI therapy
• Diabetic retinopathy (SUSTAIN-6 showed a small increased risk of retinopathy complications; ophthalmology clearance recommended)

If yes, get specialist clearance before starting.

If no, proceed to step 4.

Step 4: Can you commit to long-term treatment (12+ months)?

• Semaglutide is most effective as a long-term therapy
• Stopping after 6 months typically results in regaining most lost weight
• The medication is not a short-term fix

If no, consider whether bariatric surgery or intensive lifestyle intervention might be better options.

If yes, proceed to step 5.

Step 5: Can you afford the medication for at least 12 months?

• Brand-name: $1,000 to $1,500/month (check insurance coverage)
• Compounded: $200 to $400/month (not covered by insurance)

If no, explore patient assistance programs (Novo Nordisk offers savings cards for eligible patients) or delay starting until financial situation changes.

If yes, semaglutide is appropriate to discuss with a provider.

FAQ

What is semaglutide used for? Semaglutide is FDA-approved for type 2 diabetes (Ozempic, Rybelsus) and obesity (Wegovy). It lowers blood sugar by increasing insulin secretion and reduces body weight by suppressing appetite and slowing gastric emptying. Off-label, it's sometimes used for prediabetes or metabolic syndrome.

Is semaglutide the same as Ozempic? Ozempic is a brand name for semaglutide. Ozempic specifically refers to the injectable formulation approved for diabetes at doses up to 2 mg weekly. Semaglutide is also sold as Wegovy (for obesity, up to 2.4 mg) and Rybelsus (oral, for diabetes).

How does semaglutide work for weight loss? Semaglutide binds to GLP-1 receptors in the brain and stomach. In the brain, it reduces hunger and increases satiety. In the stomach, it slows the rate food empties, which prolongs fullness. The combination leads to reduced calorie intake and sustained weight loss.

Is semaglutide safe? Semaglutide has been studied in over 10,000 patients in clinical trials with follow-up to 2 years. The most common side effects are nausea, vomiting, and diarrhea, which are usually mild and transient. Serious risks include pancreatitis (rare), gallbladder disease (2% to 3%), and thyroid C-cell tumors (seen in rodents, not confirmed in humans). It's contraindicated in patients with a history of medullary thyroid cancer.

How much weight can you lose on semaglutide? In clinical trials, patients on semaglutide 2.4 mg lost an average of 15% to 17% of body weight over 68 weeks. About half of patients lost 15% or more. Weight loss varies based on baseline weight, adherence, diet, and exercise. Patients with diabetes tend to lose slightly less than those without diabetes.

How long does it take for semaglutide to work? Appetite suppression typically begins within 1 to 2 weeks of starting treatment. Measurable weight loss appears by week 4 to 6. Maximum weight loss occurs around month 12 to 16. Blood sugar improvements appear within 4 to 8 weeks in patients with diabetes.

What's the difference between compounded semaglutide and Ozempic? Both contain the same active molecule, semaglutide. Ozempic is FDA-approved and manufactured by Novo Nordisk. Compounded semaglutide is prepared by a pharmacy and is not FDA-approved. Compounded versions are legal during drug shortages but haven't undergone the same regulatory review for safety and efficacy. Cost is typically lower for compounded versions.

Can you take semaglutide if you don't have diabetes? Yes. Wegovy (semaglutide 2.4 mg) is FDA-approved for obesity in patients without diabetes. Clinical trials included patients with and without diabetes. The medication works for weight loss regardless of diabetes status, though weight loss tends to be slightly higher in patients without diabetes.

What are the side effects of semaglutide? The most common side effects are gastrointestinal: nausea (44%), diarrhea (30%), vomiting (24%), constipation (24%), and abdominal pain (20%). Most are mild to moderate and improve after the first 8 to 12 weeks. Serious but rare side effects include pancreatitis, gallbladder disease, kidney injury (from dehydration), and allergic reactions.

Do you have to take semaglutide forever? Semaglutide is most effective as long-term treatment. Stopping the medication typically results in weight regain. In the STEP 4 trial, patients who stopped semaglutide after 20 weeks regained two-thirds of lost weight within one year. Some patients transition to a lower maintenance dose after reaching goal weight, but discontinuing entirely usually leads to relapse.

Can you drink alcohol on semaglutide? There's no direct drug interaction between semaglutide and alcohol. However, alcohol can worsen nausea and increase the risk of hypoglycemia in patients taking other diabetes medications. Alcohol also adds empty calories, which can slow weight loss. Moderate consumption (1 to 2 drinks occasionally) is generally safe, but heavy drinking is not recommended.

How do you inject semaglutide? Semaglutide is injected subcutaneously (under the skin) once weekly, typically in the abdomen, thigh, or upper arm. The injection is done with a prefilled pen (Ozempic, Wegovy) or with a syringe from a compounded vial. Rotate injection sites each week. The medication can be taken any day of the week, at any time, with or without food.

What happens if you miss a dose of semaglutide? If you miss a dose and it's been less than 5 days since the missed dose, take it as soon as you remember. If it's been more than 5 days, skip the missed dose and resume your regular schedule. Don't double up. Missing occasional doses reduces effectiveness but isn't dangerous.

Can semaglutide cause thyroid cancer? Animal studies showed thyroid C-cell tumors in rats and mice given high doses of semaglutide. Human clinical trials have not confirmed this risk. Over 10,000 patients have been studied with no clear signal of increased thyroid cancer. However, the FDA requires a black-box warning, and semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma.

Does semaglutide cause muscle loss? Weight loss from any method includes some muscle loss. In the STEP 1 trial, about 25% to 30% of weight lost was lean mass (muscle, water, bone). This is comparable to weight loss from diet and exercise alone. Resistance training and adequate protein intake (1.2 to 1.6 g per kg body weight) can minimize muscle loss during treatment.

Sources

1. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial). New England Journal of Medicine. 2021.
3. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021.
4. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3 trial). JAMA. 2021.
5. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity (STEP 4 trial). JAMA. 2021.
6. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
7. Hjerpsted JB et al. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes Obesity and Metabolism. 2018.
8. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular Metabolism. 2021.
9. Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metabolism. 2018.
10. Buckley ST et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Science Translational Medicine. 2018.
11. Lau J et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. Journal of Medicinal Chemistry. 2015.
12. Smits MM et al. GLP-1 based therapies: clinical implications for gastric emptying. Diabetes Obesity and Metabolism. 2016.
13. FDA Drug Shortages Database. Semaglutide injection shortage updates. 2022-2026.
14. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes Obesity and Metabolism. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.